CLAIMS

~~What is claimed is:~~

1. ~~A method for treating retinitis pigmentosa in a mammal, comprising administering to the eye of the mammal a recombinant adeno-associated virus (~~rAAV~~) viral~~ particle comprising ~~a rAAV vector comprising~~ nucleic acid encoding a miR-708~~.~~

~~2. A method for treating endoplasmic reticulum (ER) stress in a cell of a mammal, comprising administering to the mammal a rAAV viral particle comprising a rAAV vector comprising~~ and nucleic acid encoding ~~a miR-708.~~

~~3. The method of claim 2, wherein the rAAV particle is administered to an eye of the mammal, optionally wherein the mammal has or is at risk of having retinitis pigmentosa.~~

~~4. The method claim 2 or 3, wherein the cell is an ocular cell.~~

~~5. The method of claim 4, wherein the cell is a photoreceptor cell.~~

~~6. The method of claim 5, wherein the cell is a rod photoreceptor cell.~~

~~7. The method of any one of claims 1-6, wherein the method comprises reducing one or more cellular markers of ER stress.~~

~~8. The method of claim 7, wherein the one or more cellular marker of ER stress is spliced XBP-1, CHOP or Grp78.~~

~~9. The method of any one of claims 1-8, wherein the rAAV vector comprises nucleic acid encodes miR-708 and~~ rhodopsin.

~~10. The method of any one of claims 1-8, further comprising administering to the eye of the mammal a second rAAV viral particle comprising a second rAAV vector comprising~~

2. The rAAV particle of claim 1, wherein the nucleic acid encoding miR-708 and/or the nucleic acid encoding rhodopsin~~.~~

~~11. A method for treating retinitis pigmentosa in a mammal, comprising administering to the eye of the mammal or the cell a rAAV viral particle comprising a rAAV vector comprising nucleic acid encoding a miR-708 and rhodopsin.~~

~~12. The method of any one of claims 1-11, wherein the nucleic acid encoding miR-708~~ is operably linked to a promoter.

~~13.~~

3. The ~~method~~rAAV particle of claim ~~12~~2, wherein the promoter ~~is capable of expressing~~expresses the miR-708 and/or rhodopsin in photoreceptor cells.

~~14.~~

4. The ~~method~~rAAV particle of claim ~~12~~2 or ~~13~~3, wherein the promoter comprises a ~~rhodopsin kinase (~~RK~~)~~ promoter ~~or~~, an opsin promoter~~.~~

~~15.The method of any one of claims 9-11, wherein the nucleic acid encoding rhodopsin is operably linked to a~~, or a CBA promoter.

~~16. The method of claim 15, wherein the promoter is capable of expressing the rhodopsin in photoreceptor cells.~~

~~17. The method of claim 15 or 16, wherein the promoter comprises a RK promoter or an opsin promoter.~~

~~18.The method of claim 9~~

5. The rAAV particle of claim 4, wherein i) the nucleic acid encoding miR-708 and the nucleic acid encoding rhodopsin are operably linked to one RK promoter or opsin promoter; or ii) the nucleic acid encoding miR-708 is operably linked to a first RK promoter or a first opsin promoter and the nucleic acid encoding rhodopsin is operably linked to a second RK promoter or a second opsin promoter.

~~19.~~

6. The ~~method~~rAAV particle of claim ~~18~~5, wherein the nucleic acid encoding miR-708 is ~~5'~~5' to the nucleic acid encoding rhodopsin~~.~~

~~20.The method of claim 18,~~ or wherein the nucleic acid encoding miR-708 is ~~3' to~~3'to the nucleic acid encoding rhodopsin.

~~21. The method of claim 12 or 15, wherein the promoter is the chicken β-actin (CBA) promoter.~~

~~22. The method of any one of claims 12-21, wherein a sequence derived from a minute virus of mouse (MVM) intron is located 3' to the promoter , wherein optionally the MMV intron comprises the nucleotide sequence of SEQ ID NO:23.~~

~~23. The method of any one of claims 12-22, wherein the promoter further comprises~~

~~i) a CMV enhancer;~~

~~ii) a sequence derived from a photoreceptor specific transcription factor;~~

~~iii) a sequence derived from a rod photoreceptor specific transcription factor;~~

~~iv) a sequence derived from a neural retinal basic zipper factor;~~

~~v) a sequence derived from a cone rod homeobox-containing transcription factor sequence;~~

~~vi) a CMV enhancer and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor; a sequence derived from a cone rod homeobox-containing transcription factor sequence,;~~

~~vii) a neural retinal basic leucine zipper factor, a CMV enhancer and an Opsin promoter (-500 to +17);~~

~~viii) a neural retinal basic leucine zipper factor, a CMV enhancer, an Opsin promoter (-500 to +17), and an MVM intron;~~

~~ix) a CMV enhancer comprising SEQ ID NO:29;~~

~~x) a neural retinal basic leucine zipper factor sequence comprising SEQ ID NO:30;~~

~~xi) a sequence derived from a cone rod homeobox-containing transcription factor sequence comprising SEQ ID NO:28;;~~

~~xii) a CMV enhancer comprising SEQ ID NO:29 and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor comprising SEQ ID NO:30; a sequence derived from a cone rod homeobox-containing transcription factor sequence comprising SEQ ID NO:28;~~

~~xiii) a neural retinal basic leucine zipper factor comprising SEQ ID NO:30, a CMV enhancer comprising SEQ ID NO:29 and an Opsin promoter (-500 to +17) comprising SEQ ID NO:22; or~~

~~xiv) a neural retinal basic leucine zipper factor comprising SEQ ID NO:30, a CMV enhancer comprising SEQ ID NO:29, an Opsin promoter (-500 to +17) comprising SEQ ID NO:22, and an MVM intron comprising SEQ ID NO:23.~~

~~24.The method~~
7. The rAAV particle of any one of claims 1-~~23~~6, wherein the nucleic acid encoding miR-708 is embedded in an intron.
~~25.~~
8. The ~~method~~rAAV particle of any one of claims 1-~~24~~7, wherein the nucleic acid encoding miR-708 comprises an endogenous miR-708 scaffold or a miR-155 scaffold.
~~26.~~
9. The ~~method~~rAAV particle of any one of claims ~~9-25 wherein the rhodopsin is human rhodopsin.~~

~~27. The method of any one of claims 9-26~~1-8, wherein the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence or lacks the 3'UTR miR-708 target sequence, wherein the substitution, insertion or deletion reduces or prevents recognition by miR-708.

~~28.~~

10. The ~~method of claim 27, wherein the substitution, insertion or deletion reduces or prevents recognition by miR-708.~~

~~29. The method~~ rAAV particle of any one of the preceding claims ~~9-28, wherein the rhodopsin lacks the 3' untranslated region (UTR) miR-708 target sequence.~~

~~30. The method of any one of claims 9-29~~, wherein the nucleic acid encoding ~~rhodopsin~~miR-708 comprises ~~a substitution, insertion or deletion of~~ the nucleic acid ~~in the miR-708 target sequence wherein the miR-708 target sequence is~~ of SEQ ID NO:~~19.~~

~~31. The method of any one of claims 9-30, wherein expression of the rhodopsin is refractory to suppression by miR-708.~~

~~32. The method of any one of claims~~ 1~~-31, wherein the nucleic acid encoding miR-708 comprises the nucleic acid of SEQ ID NO:1.~~

~~33. The method of any one of claims 1-31,~~, or wherein the nucleic acid encoding miR-708 comprises a nucleic acid having ~~about~~ at least ~~85~~90% identity to SEQ ID NO: 1~~.~~

~~34. The method of any one of claims 9-33,~~; and wherein the rhodopsin comprises the amino acid sequence of SEQ ID NO: 2~~.~~

~~35. The method of any one of claims 9-33,~~, or wherein the rhodopsin comprises an amino acid sequence having about at least ~~85~~90% identity to SEQ ID NO:2~~.~~

~~36. The method of any one of claims 9-34,~~, or wherein the nucleic acid encoding the rhodopsin comprises nucleic acid of SEQ ID NO:3~~.~~

~~37. The method of any one of claims 9-34,~~, or wherein the nucleic acid encoding the rhodopsin comprises a nucleic acid having ~~about 85~~90% identity to SEQ ID NO: 3.

~~38.~~

11. The ~~method~~rAAV particle of ~~any one of claims~~claim 1~~-8 or 10~~, wherein the ~~AAV viral~~rAAV particle comprises a recombinant viral genome comprising a polynucleotide of SEQ ID NO:5~~.~~

~~39. The method of any one of claims 1-9~~, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or ~~11,~~SEQ ID NO:27; or wherein the ~~AAV viral~~rAAV particle comprises

a recombinant viral genome ~~comprising~~comprises a polynucleotide ~~of~~having at least 90% identity to SEQ ID NO:5, SEQ ID NO:6 SEQ ID NO:7, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.

~~40.~~

12. The ~~method~~rAAV particle of any one of the preceding claims ~~1-8 or 10~~, wherein the ~~AAV viral~~rAAV particle comprises ~~a recombinant viral genome comprising a polynucleotide having about at least 85% identity to SEQ ID NO:5.~~

~~41. The method of any one of claims 1-9 or 11, wherein the AAV viral particle comprises a recombinant viral genome comprising a polynucleotide having about at least 85% identity to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.~~

~~42. The method of any one of claims 1-41, wherein the AAV viral particle and/or the second AAV viral particle comprises an~~ AAV1, AAV2, AAV3, AAV4, AAV5, AAV5 tyrosine mutant, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid~~.~~

~~43. The method of any one of claims 1-42, wherein the rAAV viral particle~~; and~~/or the second rAAV viral particle comprise an AAV serotype 5 capsid.~~

~~44. The method of claim 43, wherein the rAAV viral particle and/or the second rAAV viral particle comprise an AAV serotype 5 tyrosine mutant capsid.~~

~~45. The method of any one of claims 1-44,~~ wherein the rAAV vector ~~and/or the second rAAV vector comprise~~comprises AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype inverted terminal repeats (ITRs).

~~46.~~

13. The ~~method~~rAAV particle claim ~~45~~11, wherein the rAAV ~~vector and/or the second rAAV vector comprise AAV serotype 2 ITRs.~~

~~47. The method of any one of claims 1-46, wherein the ITR and the capsid of the rAAV viral particle are derived from the same AAV serotype.~~

~~48. The method of any one of claims 1-46, wherein the ITR and the capsid of the rAAV viral particles are derived from different AAV serotypes.~~

~~49. The method of claim 48, wherein the rAAV viral~~ particle comprises an AAV-5 capsid~~, and wherein the vector comprises AAV2 ITRs.~~

50. The method of claim 48 or 49, wherein the rAAV viral particle comprises or an AAV-5 tyrosine mutant capsid, and wherein the vector comprises AAV2 ITRs.

51. The method

14. A composition comprising the rAAV particle of any one of claims 1-50, wherein the rAAV particles are injected into the subretinal space of the retina of the mammal13.

52. The method of claim 51, wherein the

15. A composition comprising a first rAAV is administered to more than one location of the subretinal space of the retina of the mammal.

53. The method of any one of claims 1-51, wherein the rAAV particles are injected intravitreally to the mammal.

54. The method of any one of claims 1-53, wherein at least 10-30% of the photoreceptor cells are transduced by the AAV.

55. The method of any one of claims 1-54, wherein the mammal has a mutation in the endogenous rhodopsin gene.

56. The method of claim 55, wherein the mutation in the endogenous rhodopsin gene is an autosomal dominant mutation.

57. The method of any one of claims 1 or 3-56, wherein the retinitis pigmentosa is autosomal dominant retinitis pigmentosa or autosomal recessive retinitis pigmentosa.

58. The method of any one of claims 1-59, wherein the mammal is a human.

59. The method of claim 58, wherein the human has a P23H mutation in the endogenous rhodopsin gene.

60. The method of claim 10, wherein the rAAV viral particle encoding the miR-708 and the second rAAV viral particle encoding the rhodopsin are administered to the mammal at the same time or the rAAV viral particle encoding the miR-708 and the rAAV viral particle encoding the rhodopsin are administered to the mammal sequentially.

61. The method of claim 60, wherein the rAAV viral particle encoding the miR-708 is administered to the mammal first and the rAAV viral particle encoding the rhodopsin is administered to the mammal second or the rAAV viral particle encoding the rhodopsin is administered to the mammal first and the rAAV viral particle encoding the miR-708 is administered to the mammal second.

~~62. The method of any one of claims 1-60, wherein the rAAV viral particles are in a pharmaceutical composition, wherein optionally the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.~~

~~63. A rAAV particle, and optionally a second rAAV particle according to any one of claims 1-62.~~

~~64. The rAAV particle, and optionally the second rAAV particle of claim 63 for use in the methods of any one of claims 1-62.~~

~~65. A rAAV particle~~comprising a rAAV vector comprising nucleic acid encoding ~~a~~ miR-708~~.~~

~~66. The~~, and a second rAAV particle ~~of claim 65, wherein the~~comprising a rAAV vector comprising nucleic acid encoding ~~a miR-708 further encodes~~ rhodopsin.

~~67. The rAAV particle~~

16. Use of ~~claim 65, further comprising a second rAAV viral particle comprising a second rAAV vector comprising nucleic acid encoding a rhodopsin.~~

~~68. The~~a rAAV particle of any one of claims ~~65-67, wherein the nucleic acid encoding miR-708 is operably linked to a promoter.~~

~~69. The rAAV particle~~ 1-13 or a composition of claim ~~68~~14 or 15 in the preparation of a medicament for treating retinitis pigmentosa in a mammal, wherein the ~~promoter is capable of expressing the miR-708 in photoreceptor cells~~retinitis pigmentosa is associated with a mutation in the endogenous rhodopsin gene in the mammal.

~~70. The rAAV particle~~

17. Use of ~~claim 68 or 69, wherein the promoter comprises a RK promoter or an opsin promoter.~~

~~71. The~~a rAAV particle of any one of claims ~~66~~1-13 or ~~67, wherein the nucleic acid encoding~~a composition of claim 14 or 15 in the preparation of a medicament for treating endoplasmic reticulum (ER) stress in a cell of a mammal, wherein the ER stress is associated with a mutation in the endogenous rhodopsin ~~is operably linked to a promoter.~~

~~72. The rAAV particle of claim 71, wherein the promoter is capable of expressing the rhodopsin in photoreceptor cells.~~

~~73. The rAAV particle of claim 71 or 72, wherein the promoter comprises a RK promoter or an opsin promoter.~~

~~74. The rAAV particle of any one of claim 73, wherein i) the nucleic acid encoding miR-708 and the nucleic acid encoding rhodopsin are operably linked to one RK promoter or opsin promoter; or ii) the nucleic acid encoding miR-708 is operably linked to a first RK promoter or a first opsin promoter~~

and the nucleic acid encoding rhodopsin is operably linked to a second RK promoter or a second opsin promoter.

75. The rAAV particle of claim 74, wherein the nucleic acid encoding miR-708 is 5' to the nucleic acid encoding rhodopsin.

76. The rAAV particle of claim 74, wherein the nucleic acid encoding miR-708 is 3' to the nucleic acid encoding rhodopsin.

77. The rAAV particle of claim 68 or 71, wherein the promoter is the chicken β-actin (CBA) promoter.

78. The rAAV particle of any one of claims 68-77, wherein a sequence derived from a minute virus of mouse (MVM) intron is located 3' to the promoter, wherein optionally the MMV intron comprises the nucleotide sequence of SEQ ID NO:23.

79. The method of any one of claims 68-78, wherein the promoter further comprises

i) a CMV enhancer;

ii) a sequence derived from a photoreceptor specific transcription factor;

iii) a sequence derived from a rod photoreceptor specific transcription factor;

iv) a sequence derived from a neural retinal basic zipper factor;

v) a sequence derived from a cone rod homeobox-containing transcription factor sequence;

vi) a CMV enhancer and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor; a sequence derived from a cone rod homeobox-containing transcription factor sequence;

vii) a neural retinal basic leucine zipper factor, a CMV enhancer and an Opsin promoter (-500 to +17);

viii) a neural retinal basic leucine zipper factor, a CMV enhancer, an Opsin promoter (-500 to +17), and an MVM intron;

ix) a CMV enhancer comprising SEQ ID NO:29;

x) a neural retinal basic leucine zipper factor sequence comprising SEQ ID NO:30;

xi) a sequence derived from a cone rod homeobox-containing transcription factor sequence comprising SEQ ID NO:28;;

xii) a CMV enhancer comprising SEQ ID NO:29 and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor comprising SEQ ID NO:30; a sequence derived from a cone rod homeobox-containing transcription factor sequence comprising SEQ ID NO:28;

xiii) a neural retinal basic leucine zipper factor comprising SEQ ID NO:30, a CMV enhancer comprising SEQ ID NO:29 and an Opsin promoter (-500 to +17) comprising SEQ ID NO:22; or

xiv) a neural retinal basic leucine zipper factor comprising SEQ ID NO:30, a CMV enhancer comprising SEQ ID NO:29, an Opsin promoter (-500 to +17) comprising SEQ ID NO:22, and an MVM intron comprising SEQ ID NO:23.

80. The rAAV particle of any one of claims 65-79, wherein the nucleic acid encoding miR-708 is embedded in an intron.

81. The rAAV particle of any one of claims 65-80, wherein the nucleic acid encoding miR-708 comprises an endogenous miR-708 scaffold or a miR-155 scaffold.

82. The rAAV particle of any one of claims 66-81, wherein the rhodopsin is human rhodopsin.

83. The method of any one of claims 66-82, wherein the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence.

84. The method of claim 83, wherein the substitution, insertion or deletion reduces or prevents recognition by miR-708.

85. The rAAV particle of any one of claims 66-84, wherein the rhodopsin lacks the 3' UTR miR-708 target sequence.

86. The rAAV particle of any one of claims 66-85, wherein the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence wherein the miR-708 target sequence is SEQ ID NO:19.

87. The rAAV particle of any one of claims 65-86, wherein expression of the rhodopsin is refractory to suppression by miR-708.

~~88. The rAAV particle of any one of claims 65-87, wherein the nucleic acid encoding miR-708 comprises the nucleic acid of SEQ ID NO:1.~~

~~89. The rAAV particle of any one of claims 65-88, wherein the nucleic acid encoding miR-708 comprises a nucleic acid having about at least 85% identity to SEQ ID NO:1.~~

~~90. The rAAV particle of any one of claims 66-89, wherein the rhodopsin comprises the amino acid sequence of SEQ ID NO:2.~~

~~91. The rAAV particle of any one of claims 66-90, wherein the rhodopsin comprises an amino acid sequence having about at least 85% identity to SEQ ID NO:2.~~

~~92. The rAAV particle of any one of claims 66-90, wherein the nucleic acid encoding the rhodopsin comprises nucleic acid of SEQ ID NO:3.~~

~~93. The rAAV particle of any one of claims 66-90, wherein the nucleic acid encoding the rhodopsin comprises a nucleic acid having about 85% identity to SEQ ID NO:3.~~

~~94. The rAAV particle of claim 65 or 66, wherein the AAV viral particle comprises a recombinant viral genome comprising a polynucleotide of SEQ ID NO:5.~~

~~95. The rAAV particle of any one of claims 66 or 68-73, wherein the AAV viral particle comprises a recombinant viral genome comprising a polynucleotide of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.~~

~~96. The rAAV particle of claim 65 or 67, wherein the AAV viral particle comprises a recombinant viral genome comprises a polynucleotide having about at least 85% identity to SEQ ID NO:5.~~

~~97. The rAAV particle of any one of claims 66 or 68-73, wherein the AAV viral particle comprises a recombinant viral genome comprises a polynucleotide having about at least 85% identity to SEQ ID NO:6 SEQ ID NO:7, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.~~

~~98. The rAAV particle of any one of claims 65-97, wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid.~~

~~99. The rAAV particle of any one of claims 65-98, wherein the rAAV viral particle comprises an AAV serotype 5 capsid.~~

~~100. The rAAV particle of claim 98 or 99, wherein the rAAV viral particle comprises an AAV serotype 5 tyrosine mutant capsid.~~

~~101. The rAAV particle of any one of claims 65-100, wherein the rAAV vector comprises AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype inverted terminal repeats (ITRs).~~

~~102. The rAAV particle of any one of claims 65-101, wherein the vector comprises AAV serotype 2 ITRs.~~

~~103. The rAAV particle of any one of claims 65-102, wherein the ITR and the capsid of the rAAV viral particle are derived from the same AAV serotype.~~

~~104. The rAAV particle of any one of claims 65-102, wherein the ITR and the capsid of the rAAV viral particles are derived from different AAV serotypes.~~

~~105. The rAAV particle of claim 104, wherein the rAAV viral particle comprises an AAV-5 capsid, and wherein the vector comprises AAV2 ITRs.~~

~~106. The rAAV particle of claim 105, wherein the rAAV viral particle comprises an AAV-5 tyrosine mutant capsid, and wherein the vector comprises AAV2 ITRs.~~

~~107. A composition comprising the rAAV particle of any one of claims 65-106.~~

~~108. A composition comprising a rAAV particle comprising a rAAV vector comprising nucleic acid encoding miR-708 according to any one of claims 1-62, and optionally a second rAAV particle comprising a rAAV vector comprising nucleic acid encoding rhodopsin, used in the methods of any one of claims 1-62.~~

~~109. The composition of claim 107 or 108 for use in the method of any one of claims 1-62.~~

~~110. The composition of any one of claims 107-108, wherein the composition is a pharmaceutical composition, wherein optionally the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.~~

~~111. A kit comprising an effective amount of rAAV particles according to the methods of any one of claims 1-62.~~

~~112. A kit comprising an effective amount of rAAV particles according to any one of claims 63-106.~~

~~113. A kit comprising an effective amount of the composition of any one of claims 107-110.~~

~~114. A kit comprising an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708.~~

~~115. A kit comprising an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 and rhodopsin.~~

~~116. A kit comprising an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 and an effective amount of second rAAV particles comprising a second rAAV vector comprising nucleic acid encoding rhodopsin.~~

~~117. The kit of any one of claims 118-122, further comprising instructions for use of the rAAV particles~~gene in the ~~treatment of retinitis pigmentosa and/or treatment of ER stress.~~

~~118. An article of manufacture comprising an effective amount of rAAV particles according to the methods of any one of claims 1-62.~~

~~119. An article of manufacture comprising an effective amount of rAAV particles according to any one of claims 63-106.~~

~~120. An article of manufacture comprising an effective amount of the composition of any one of claims 107-110.~~

~~121. An article of manufacture comprising an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708.~~

~~122. An article of manufacture comprising an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 rhodopsin.~~

~~123. An article of manufacture comprising an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 and an effective amount of second rAAV particles comprising a second rAAV vector comprising nucleic acid encoding rhodopsin.~~

~~124. A nucleic acid comprising an intron derived from an MVM.~~

~~125. The nucleic acid of claim 124 wherein the MVM intron comprises SEQ ID NO:23.~~

126. The nucleic acid of claim 124 or 125, further comprising a promoter and optionally an enhancer.

127. The nucleic acid of claim 126, wherein the promoter is located 5' to the MVM intron.

128. An expression construct comprising the nucleic acid of any one of claims 124-127.

129. A vector comprising the nucleic acid of any one of claims 124-127 or the expression construct of claim 128.

130. A cell comprising the nucleic acid of any one of claims 124-127, the expression construct of claim 128 or the vector of claim 129mammal.